Precision Medicine in Oncology: Incorporating Cancer Genomics into Patient Care
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes
In this webcast, expert faculty discuss how to guide the treatment of cancer patients through the interpretation of genetic testing results and how the role of making targeted alterations to the genome are changing the current oncologic treatment options on the market. This webcast increases educational opportunities to all members of oncologic care teams and improves the understanding of genetic sequencing and the use of genomic alterations evolving the landscape of oncology. Included in the presentation are patient cases intended to prompt learners into applying the information and help guide them toward appropriate treatment options using realistic scenarios.
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
1. Discuss how to interpret genetic test results for a cancer patient
2. Identify how sequencing results guide cancer treatment decisions in real-world patient cases
3. Describe the role of targeting genomic alterations in the current oncologic treatment landscape
Christine M. Walko, PharmD, BCOP, FCCP
Associate Member Department of Individualized
Cancer Management Precision Medicine
Team Lead Moffitt Cancer Center Tampa, FL
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Dr Christine Walko has served on Tumor Boards for Intermountain Health and Jackson Genetic Labs during the past 12 months.
Dr. Walko will discuss off label indications for United Stated Food and Drug Administration (FDA) approved drugs by the nature of the talk content
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form.
Access to the internet is required.
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above